



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc



Corrigendum

Corrigendum to “Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554” [Bioorg. Med. Chem. 19 (2011) 4482–4498]

Hironobu Maezaki^{a,*}, Yoshihiro Banno^{a,†}, Yasufumi Miyamoto^a, Yusuke Moritoh^a, Tomoko Asakawa^a, Osamu Kataoka^{a,†}, Koji Takeuchi^a, Nobuhiro Suzuki^a, Koji Ikeda^a, Takuo Kosaka^a, Masako Sasaki^a, Shigetoshi Tsubotani^a, Akiyoshi Tani^a, Miyuki Funami^{a,‡}, Yoshio Yamamoto^a, Michiko Tawada^a, Kathleen Aertgeerts^b, Jason Yano^b, Satoru Oi^{a,‡}

^a Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohomachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan

^b Takeda San Diego, Inc., 10410, Science Center Drive, San Diego, CA 92121, USA

The name of Yusuke Moritoh mistakenly appeared as Yuusuke Moritou in the author line. The correct author line appears above.

DOI of original article: [10.1016/j.bmc.2011.06.032](https://doi.org/10.1016/j.bmc.2011.06.032)

* Corresponding author. Tel.: +81 466 32 1106; fax: +81 466 29 4449.

E-mail address: Maezaki_Hironobu@takeda.co.jp (H. Maezaki).

[†] Present address: 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

[‡] Present address: Pharmaceutical Production Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohomachi 2-chome Yodogawa-ku, Osaka 532-8686, Japan.